Taxotere lawsuit

October 18, 2017

Taxotere Hair Loss lawsuits in settlement discussion

Taxotere Hair Loss lawsuits in settlement discussion. According to sources, the Taxotere hair loss lawsuits may be in preliminary stages of settlement talks.

The judge overseeing the multidistrict litigation in the Taxotere chemotherapy drug products liability litigation has ordered plaintiff attorneys to file information about all pending and anticipated claims “so that “claimants may have the opportunity to participate in any eventual resolution process.”

U.S. District Judge Kurt Engelhardt issued Pretrial Order No. 60A to the Plaintiff’s Settlement Committee on September 15, with uploading of the census data by October 31. Generally speaking, the compilation of data about the injured plaintiffs is usually the first step in a global mass tort settlement.

June 7, 2016

Taxotere lawsuits on the rise over permanent hair loss

by Dr. Shezad Malik

Cancer patients receiving chemotherapy understand there is a risk of hair loss involved. In fact, along with nausea, hair loss is the most common and well known side effect of cancer drugs. Cancer paitents tolerate hair loss as a side effect because of the hope that the drug will save their lives and the knowledge that their hair will grow back after cancer treatment.

But a growing number of lawsuits filed against the makers of Taxotere allege that the company failed to warn patients that Taxotere may cause permanent hair loss. The lawsuits also claim that the drug manufacturer actively encouraged doctors to use Taxotere despite its risks and despite the availability of other, safer cancer treatments.

Taxotere was first approved by the FDA in 1996. It was a more powerful version of another chemotherapy drug that had already been approved for use. Taxotere has been approved for the treatment of metastatic prostate cancer, non-small cell lung cancer, neck and head cancer, advance stomach cancer and breast cancer. It is also being investigated as a possible treatment for other cancers, including small cell lung cancer and pancreatic cancer.

May 19, 2016

Cancer survivor files lawsuit against Taxotere

by Dr. Shezad Malik

A lawsuit filed in California alleges that the makers of a popular chemotherapy drug misrepresented the drug’s benefits and hid side effects, including permanent hair loss.

Breast cancer survivor Ami Dodson filed a lawsuit against the makers of Taxotere (docetaxel) claiming the drug caused her to suffer permanent hair loss (alopecia). She also claims the drug maker engaged in marketing schemes to drive up the sales of the drug while hiding medication’s increased toxicity level compared to other similar drugs.

About 75 percent of all women who suffer from breast cancer in the United States are prescribed Taxotere.

April 29, 2016

Taxotere permanent hair loss side effect raises questions

by Dr. Shezad Malik

Nearly 75 percent of women in the United States with breast cancer have been prescribed Taxotere as part of chemotherapy. Medical professionals are now taking a second look at the drug after reports suggests that it might lead to permanent hair loss.

Taxotere lawsuits on the rise According to a lawsuit filed by Ami Dodson, the drug caused her to suffer from permanent hair loss. Dodson’s lawsuit also alleges that the makers of Taxotere engaged in marketing schemes to drive up the sales of the drug while hiding the medication’s increased toxicity compared to other similar drugs.

“Defendants [preyed] on one of the most vulnerable group of individuals at the most difficult time in their lives,” Dodson alleges. “Defendants obtained billions of dollars in increased revenues at the expense of unwary cancer victims simply hoping to survive their condition and return to a normal life.”

April 14, 2016

Taxotere permanent hair loss lawsuit

by Dr. Shezad Malik

Although hair loss is a common side effect of chemotherapy, permanent hair loss is not. However, as lawsuits against the makers of Taxotere are beginning to reveal, that is not always the situation.

The FDA approved Taxotere (docetaxel) in 1996 for treatment of breast cancer. Taxotere has since been used to treat several other types of cancers including non-small lung cancer, prostate cancer, gastric cancer, and head and neck cancer. While Taxotere is an effective cancer drug, lawsuits filed against the makers of Taxotere allege that the drug causes permanent hair loss.

Cancer patients who filed the lawsuit say that the makers of Taxotere failed to inform them or their doctors that a potential side effect of the drug could be permanent hair loss, also known as Taxotere alopecia. Although the Taxotere label has always mentioned hair loss as a possible side effect, there was no mention that the hair loss could be permanent.